NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata
Executive Summary
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
You may also be interested in...
Minute Insight: Inivata's RaDaR Assay Study Yields Encouraging Results
RaDaR, a test for head and neck squamous cell carcinoma, demonstrated high efficacy in a new study.
Inivata Continues Trials Of Its Liquid Biopsy Platform
The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.
Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.